组织悬液HER2阳性标本在免疫组化室内质控中作为阳性对照的作用和价值  

Role and Value of Tissue Suspension HER2 Positive Specimen as Positive Contrast in the Quality Control of Immunohistochemistry

作　　者：吴景 何杰[1] WU Jing;HE Jie(Department of Pathology,West District of the First Affiliated Hospital of University of Science & Technology of China //Anhui Provincial Cancer Hospital,Hefei 230031,China)

机构地区：[1]中国科学技术大学附属第一医院西区//安徽省肿瘤医院病理科

出　　处：《中山大学学报（医学版）》2019年第5期683-688,共6页Journal of Sun Yat-Sen University:Medical Sciences

基　　金：国家自然科学基金(81272800)

摘　　要：【目的】为了更好的建立人类表皮生长因子受体2(HER2)免疫组化室内质控,探讨一种简易的HER2阳性对照方法。【方法】收集2015年1月至2018年12月安徽省肿瘤医院乳腺癌根治标本,挑选20例HER2表达3+的肿瘤样本制作成组织悬液,分别经HE染色及免疫组化染色证实癌细胞HER2的表达,1个月及3个月后再次HER2免疫组化验证。选取乳腺癌、胃癌HER2明确表达0、1+、2+、3+的归档蜡块与作为对照的悬液样本进行HER2染色对比。【结果】20例组织悬液中的癌细胞HER2定位明确,染色强度3+,3个月后再次染色结果无差异,可为乳腺癌、胃癌HER2染色提供阳性参考。【结论】组织悬液HER2阳性对照可作为免疫组化室内质控使用,该方法简便、可靠、实用、易推广。【Objective】To explore a simple positive contrast method for better quality control of HER2 immunohisto-chemistry.【Methods】Breast cancer radical treatment specimens from Anhui Cancer Hospital from January 2015 to December 2018 were collected. Among these specimens,20 tumor samples with HER2 expression of 3+ were selected and prepared into tissue suspension. HER2 expression in cancer cells was confirmed by HE staining and immunohisto-chemical staining respectively,and verified again after 1 month and 3 months. Wax blocks with HER2 expression of 0, 1+,2+ and 3+ in breast cancer and gastric cancer,were selected from archived database for HER2 staining comparison with the suspension as a contrast.【Results】The HER2 localization of cancer cells in 20 tissue suspension was clear ,the staining intensity was 3+. The staining effect of tissue suspension was as same after 3 months,and could provide positive reference for HER2 staining of breast cancer and gastric cancer.【Conclusion】The HER2 positive contrast of tissue suspension could be used as immunohistochemical internal quality control,which is simple,reliable,practical,and easy to popularize.

关 键 词：组织悬液 HER2 免疫组化 质量控制 

分 类 号：R361.2[医药卫生—病理学]